April 24, 2025
TOPLINE: Low-grade systemic inflammation, indicated by elevated levels of Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP), was associated with a higher risk […]
April 23, 2025
TOPLINE: Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria (CSU) unresponsive […]
April 21, 2025
ORLANDO, Florida — Two lasers developed specifically to target the sebaceous gland were cleared by the US Food and Drug Administration (FDA) for the treatment of […]
April 21, 2025
TOPLINE: A panel of dermatologists reached a consensus on 23 topical ingredients that they considered useful for seven common skin concerns, with retinoids recommended for five […]
April 18, 2025
The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who […]
April 17, 2025
TOPLINE: A recent study identified three clinically distinct vitiligo profiles on the basis of Vitiligo Patient Priority Outcomes (ViPPO) responses from real-world patient data. Classes with […]
April 17, 2025
A recent case report explains how epitope spread may cause immune checkpoint inhibitor (ICI)–associated bullous pemphigoid (BP). A separate research letter spotlights cases of partial lipodystrophy […]
April 16, 2025
TOPLINE: A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved clinical outcomes in patients with drug reaction with […]
April 11, 2025
TOPLINE: An autonomous total body photographic (TBP) and dermoscopic imaging device achieved comparable image quality and faster acquisition times than manual dermoscopy, in a prospective cohort […]